WO2009033824A1 - Utilisation d'une combinaison de bêta-casoquinine et de cnp-22 en tant qu'agent thérapeutique - Google Patents

Utilisation d'une combinaison de bêta-casoquinine et de cnp-22 en tant qu'agent thérapeutique Download PDF

Info

Publication number
WO2009033824A1
WO2009033824A1 PCT/EP2008/008192 EP2008008192W WO2009033824A1 WO 2009033824 A1 WO2009033824 A1 WO 2009033824A1 EP 2008008192 W EP2008008192 W EP 2008008192W WO 2009033824 A1 WO2009033824 A1 WO 2009033824A1
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
disease
diseases
gly
disorders
Prior art date
Application number
PCT/EP2008/008192
Other languages
English (en)
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Laboratories Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories Ag filed Critical Mondobiotech Laboratories Ag
Publication of WO2009033824A1 publication Critical patent/WO2009033824A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • isoform in the context of prions means two proteins with exactly the same amino acid sequence that can fold into molecules with dramatically different tertiary structures.
  • the normal cellular isoform of the prion protein (PrP c ) has a high ⁇ -helix content, a low ⁇ -sheet content, and is sensitive to protease digestion.
  • the abnormal, disease-causing isoform (PrP Sc ) has a lower ⁇ -helix content, a much higher ⁇ -sheet content, and is much more resistant to protease digestion.
  • autoimmune diseases of the liver are autoimmune hepatitis (AIH type 1 , 2 and 3), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis.
  • AIH type 1 , 2 and 3 autoimmune hepatitis
  • PBC primary biliary cirrhosis
  • PSC primary sclerosing cholangitis
  • fibrosis-associated disorders include systemic sclerosis, eosinophilia-myalgia syndrome, and fibrosis-associated CNS disorders such as intraocular fibrosis.
  • Dermal fibrosing disorders include, for example, scleroderma, morphea, keloids, hypertrophic scars, familial cutaneous collagenoma, and connective tissue nevi of the collagen type.
  • Fibrotic conditions of the eye include conditions such as diabetic retinopathy, post-surgical scarring (for example, after glaucoma filtering surgery and after crossed-eyes (strabismus) surgery), and proliferative vitreoretinopathy.
  • Additional fibrotic conditions may result, for example, from rheumatoid arthritis, diseases associated with prolonged joint pain and deteriorated joints; progressive systemic sclerosis, polymyositis, dermatomyositis, eosinophilic fascitis, morphea, Raynaud's syndrome, and nasal polyposis.
  • scleroderma - Raynaud's disease; swelling of the hands, arms, legs and face; skin thickening; pain, swelling and stiffness of the fingers and knees, gastrointestinal dysfunction, restrictive lung disease; pericarditis; renal failure;
  • amino acid transmitters especially glutamate
  • oxidative stress and inflammatory reactions contribute strongly to cell death in these conditions.
  • damaged neurons Upon injury or upon ischemic insult, damaged neurons release massive amounts of the neurotransmitter glutamate, which is excitotoxic to the surrounding neurons.
  • Glutamate is a negatively charged amino acid that is an excitatory synaptic transmitter in the mammalian nervous system.
  • glutamate can reach the millimolar range in nerve terminals its extracellular concentration is maintained at a low level to prevent neurotoxicity. It has been noted that glutamate can be toxic to neurons if presented at a high concentration.
  • excitotoxicity has been used to describe the cytotoxic effect that glutamate (and other such excitatory amino acids) can have on neurons when applied at high dosages.
  • the method includes the step of; administering to a patient in need of treatment, an effective amount of one of the peptides disclosed herein in combination with an effective amount of one or more other compounds or therapeutic agents that have the ability to provide neuroprotection or to treat or prevent seizures or epileptogenesis or the ability to augment the neuroprotective effects of the compounds of the invention.
  • Therapeutic angiogenesis is the application of specific compounds which may inhibit or induce the creation of new blood vessels in the body in order to combat disease.
  • the presence of blood vessels where there should be none may affect the mechanical properties of a tissue, increasing the likelihood of failure.
  • the absence of blood vessels in a repairing or otherwise metabolically active tissue may retard repair or some other function.
  • Several diseases are the result of failure or insufficient blood vessel formation and may be treated by a local expansion of blood vessels, thus bringing new nutrients to the site, facilitating repair.
  • Other diseases may be created by a local expansion of blood vessels, interfering with normal physiological processes.
  • Angiogenesis represents an excellent therapeutic target for the treatment of, for example, cardiovascular diseases. It is a potent, physiological process that underlies the natural manner in which the human body responds to a diminution of blood supply to vital organs, namely the production of new collateral vessels to overcome the ischemic insult.
  • Vascular malformations in blood and lymph vessels like DiGeorge syndrome, hereditary haemorrhagic telangiectasia, cavernous hemangioma, cutaneous hemangioma, lymphatic malformations, transplant arteriopathy, atherosclerosis, vascular anastomoses,
  • Lung diseases like neonatal respiratory distress syndrome, pulmonary fibrosis, emphysema,
  • peptide combination of the invention can also be administered in form of its pharmaceutically active salts.
  • Suitable pharmaceutically active salts comprise acid addition salts and alkali or earth alkali salts. For instance, sodium, potassium, lithium, magnesium or calcium salts can be obtained.
  • the peptides of the present invention may also be deliverable transdermally.
  • the transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • Prior efforts to provide active agents for medication include incorporating the medication in a polymeric matrix whereby the active ingredient is released into the systemic circulation.
  • Known sustained-release delivery means of active agents are disclosed, for example, in US4235988, US4188373, US4100271 , US447471 , US4474752, US4474753, or US4478822 relating to polymeric pharmaceutical vehicles for delivery of pharmaceutically active chemical materials to mucous membranes.
  • the pharmaceutical carriers are aqueous solutions of certain polyoxyethylene-polyoxypropylene condensates.
  • These polymeric pharmaceutical vehicles are described as providing for increased drug absorbtion by the mucous membrane and prolonged drug action by a factor of two or more.
  • the substituents are block copolymers of polyoxypropylene and polyoxyethylene used for stabilization of drugs such as insulin.
  • Peptide 1 having the amino acid sequence: Tyr-Gln-Gln-Pro-Val-Leu-Gly-Pro-Val-
  • peptides in the following examples indicates that the test disclosed in the corresponding example was conducted with peptide 1 alone and peptide 2 alone and with the peptide combination generally in equimolar ratios (molar ratio about 1 : 1 for peptide 1 : peptide 2) if no other molar ratio is mentioned in the corresponding example.
  • kits can be used to measure lnterleukin-2 (IL-2), lnterleukin-4 (IL-4), lnterleukin-5 (IL-5), Interferon ⁇ (IFN- ⁇ ), and Tumor Necrosis Factor- ⁇ (TNF- ⁇ ) protein levels in a single sample.
  • the kit performance has been optimized for analysis of physiologically relevant concentrations (pg/ml levels) of specific cytokine proteins in tissue culture supernatants and serum samples.

Abstract

La présente invention concerne l'utilisation de la combinaison des composés peptidiques Tyr-Gln-Gln-Pro-Val-Leu-Gly-Pro-Val-Arg-OH et Gly-Leu-Ser-Lys-Gly- Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-lle-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH en tant que composés polythérapeutiques destinés à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
PCT/EP2008/008192 2007-09-11 2008-09-09 Utilisation d'une combinaison de bêta-casoquinine et de cnp-22 en tant qu'agent thérapeutique WO2009033824A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017755 2007-09-11
EP07017747 2007-09-11
EP07017747.2 2007-09-11
EP07017755.5 2007-09-11

Publications (1)

Publication Number Publication Date
WO2009033824A1 true WO2009033824A1 (fr) 2009-03-19

Family

ID=40289376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008192 WO2009033824A1 (fr) 2007-09-11 2008-09-09 Utilisation d'une combinaison de bêta-casoquinine et de cnp-22 en tant qu'agent thérapeutique

Country Status (1)

Country Link
WO (1) WO2009033824A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183021B1 (en) 1999-05-26 2007-02-27 Sony Corporation Solid electrolyte battery
CN102370985A (zh) * 2010-08-11 2012-03-14 中国科学院上海生命科学研究院 钠尿肽受体a的激动剂在疼痛治疗中的用途
CN112852698A (zh) * 2021-01-30 2021-05-28 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026971A1 (fr) * 1997-11-24 1999-06-03 The University Of Melbourne Peptides antimicrobiens
WO2001017548A2 (fr) * 1999-09-03 2001-03-15 Pharis Biotec Gmbh Utilisation de peptides natriuretiques comme substances a action antibiotique dans le cadre du traitement des infections bacteriennes
US20010027181A1 (en) * 2000-03-31 2001-10-04 Masafumi Kitakaze Treatment or prophylaxis of ischemic heart disease
CN1566152A (zh) * 2003-06-10 2005-01-19 天津商学院 具有抗菌作用的免疫活性肽（Trpi）
EP1759710A1 (fr) * 2004-03-31 2007-03-07 Kazuwa Nakao Remède ou médicament préventif pour l'arthrite

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026971A1 (fr) * 1997-11-24 1999-06-03 The University Of Melbourne Peptides antimicrobiens
WO2001017548A2 (fr) * 1999-09-03 2001-03-15 Pharis Biotec Gmbh Utilisation de peptides natriuretiques comme substances a action antibiotique dans le cadre du traitement des infections bacteriennes
US20010027181A1 (en) * 2000-03-31 2001-10-04 Masafumi Kitakaze Treatment or prophylaxis of ischemic heart disease
CN1566152A (zh) * 2003-06-10 2005-01-19 天津商学院 具有抗菌作用的免疫活性肽（Trpi）
EP1759710A1 (fr) * 2004-03-31 2007-03-07 Kazuwa Nakao Remède ou médicament préventif pour l'arthrite

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200582, Derwent World Patents Index; AN 2005-797816, XP002513109 *
FITZGERALD R J ET AL: "MILK PROTEIN-DERIVED PEPTIDE INHIBITORS OF ANGIOTENSIN-I-CONVERTING ENZYME", BRITISH JOURNAL OF NUTRITION, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 84, no. SUPPL. 01, 1 January 2000 (2000-01-01), pages S33 - S37, XP009033839, ISSN: 0007-1145 *
KAYSER H. AND MEISEL H.: "Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins.", FEBS LETTERS, vol. 383, 1996, pages 18 - 20, XP002513108 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183021B1 (en) 1999-05-26 2007-02-27 Sony Corporation Solid electrolyte battery
CN102370985A (zh) * 2010-08-11 2012-03-14 中国科学院上海生命科学研究院 钠尿肽受体a的激动剂在疼痛治疗中的用途
CN112852698A (zh) * 2021-01-30 2021-05-28 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用
CN112852698B (zh) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用

Similar Documents

Publication Publication Date Title
WO2009033821A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009040030A1 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009040034A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043465A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033733A2 (fr) Utilisation d'un peptide comme agent thérapeutique
WO2009043522A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
EP2187907A2 (fr) Utilisation de tyr-w-mif-1 et d'urocortine 2 en tant qu'agents thérapeutiques
WO2009039978A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046830A1 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
EP2190465A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033769A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033761A2 (fr) Utilisation d'un peptide comme agent thérapeutique
WO2009033819A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009040047A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033814A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033820A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043525A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033729A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033824A1 (fr) Utilisation d'une combinaison de bêta-casoquinine et de cnp-22 en tant qu'agent thérapeutique
WO2009033818A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033816A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046875A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033813A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043523A2 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033823A1 (fr) Utilisation d'une combinaison de peptide comprenant urotensine ii en tant qu'agent thérapeutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830278

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08830278

Country of ref document: EP

Kind code of ref document: A1